Dr. Holger Bengs Biotech Consulting - Protagen and Tomy Digital Biology advertise administration acceding for Modiro™ in Japan

Agreement provides acceptance to software for analysing post-translational modifications in Asia

Dortmund, 11 December 2007 - Protagen AG, a arch provider of products, casework and software solutions for protein research, appear today that it has entered into a administration acceding for its Bio-IT software product, Modiro™ – the PTM-Explorer with Tomy Digital Biology Co. Ltd of Tokyo, Japan.

Modiro™ was launched in the bazaar in March this year, and the antecedent sales abstracts accept approved how admired capital software for the qualitative appraisal of post-translational modifications (PTMs) is to protein researchers. Protagen has been acknowledged in accession Modiro™ in both Europe and the USA, and expects accretion sales of the artefact in these markets. Through this acceding with Tomy Digital Biology, Protagen will accretion an accustomed benefactor for the commercialisation of its artefact in the Japanese market.

Tomy Digital Biology has been accustomed for over 40 years and has a acceptable acceptability amidst Japan’s researchers, bartering analysis institutes such as the Riken-Brain Institute and the Osaka National Research Institute. The absolute rights for administration of Modiro™ in Japan accepted to Tomy Digital Biology will advice to defended its arch position as a able provider of Bio-IT software and associated products.

Post-translational protein modifications attune the action of abounding proteins and the appraisal of these changes is of growing accent in the analysis and development of new biologic candidates. Modiro™ enables advisers to analyze decidedly added of these analytical modifications application absolute mass-spectrometry data. In addition, by automating the identification of PTMs, the PTM-Explorer reduces the time bare for protein analysis.

Dr Christoph Hüls, CEO of Protagen, said: “The signing of this commercialisation acceding demonstrates the connected advanced of Protagen into the Asian market, which began with the analysis accord with Kangdi Antibody Biotech and Bejing Proteome Research Centre appear beforehand this year.”

Contact
Dr. Christoph Hüls
CEO
Protagen AG
Otto-Hahn-Str. 15
44227 Dortmund
Tel: +49 (0) 231 9742 6300
Fax: +49 (0) 231 9742 6301
E-Mail:info@protagen.com

For English media enquiries
Dr. Holger Bengs
Biotech Consulting
Tel: +49 (0) 69 6199 4273
Fax: +49 (0) 69 6199 4249
E-Mail: info@holgerbengs.de

About Protagen AG

Protagen (www.protagen.com) is a arch provider of products, casework and software solutions for protein research. Operating internationally to accommodate barter with articles and casework of the accomplished quality, Protagen has offices in Dortmund, Germany and New Jersey, USA. The Company has a decade of acquaintance in applying the a lot of beat protein analysis accoutrement and techniques to advance the ability of the biologic analysis and development process.
As an innovator in protein biochips, Protagen has developed UNIclone®, a apparent adequate belvedere for protein announcement libraries and protein arrays, and UNIchip®, a able and awful able alternation of protein biochip articles for antibiotic development. In addition, it has accustomed UNIarrayTM, a awful able technology belvedere for biomarker analysis on an automated scale. Protagen has afresh accustomed a BioChance Plus admission from the German government to analyze biomarkers for Multiple Sclerosis and Rheumatoid Arthritis.
Protagen provides barter with a adjustable account program, including protein appraisal and identification, cogwheel protein display, antibiotic validation and specification, antigen identification, and abounding abstracts administration services.
Protagen AG is abreast endemic and has bankrupt two costs rounds: at the end of 2004 and in bounce 2006. Shareholders of Protagen AG, besides the founders and the administration team, are S-Venture Capital Dortmund GmbH and MIG AG & Co KG Beteiligungsfonds 1 and 3.


About Tomy Digital Biology Co. Ltd

Tomy Digital Biology (www.digital-biology.co.jp) provides new technologies and solutions for the optimisation of analysis in the activity sciences in the post-genomic era. Various beginning methods from the three areas of in vitro, in vivo and in silico are accumulated to accomplish this. Tomy Digital Biology is the alone aggregation in Japan that food complete solutions of this kind. The Company draws on added than 40 years business acquaintance in the activity sciences arena.